IGFBP3 and myeloid sarcoma: Our analysis of serum IGFBP-3 levels considering all studies demonstrated a significant increase in serum IGFBP-3 levels reported in Lanzillo et al. [19] study, a significantly reduced serum IGFBP-3 levels in Akcali et al. and Wilczak et al. [12, 24] studies, and no difference noted in Al-Temaimi et al., Poljakovic et al., Gironi et al., and Nageeb et al. [13, 14, 17, 27] studies considering the MS group and the healthy control (Fig 8).